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Background: The human major histocompatibility complex class I polypeptide-related sequence B (MICB) is a
protein that modulates the NK and T cell activation through the NKG2D receptor and is related to several diseases
including cancer.
Methods: The study investigated the prognostic role of soluble MICB (sMICB) protein in the progression of
HBV-related liver diseases and to HBV-related HCC treatment. The sMICB serum levels were measured in 266 chronic
HBV-infected Vietnamese patients and in healthy controls, and correlated with clinical and laboratory parameters
and with therapeutic interventions for HBV-related HCC.
Results: Significant differences in both clinical and laboratory parameters were observed among the patient groups
with different stages of hepatitis. The platelet counts were significantly decreased with disease progression (P < 0.001).
The sMICB serum levels were significantly increased in HBV patients compared to healthy controls (P < 0.0001). Among
the patients with different stages of hepatitis, asymptomatic individuals (ASYM) revealed higher sMICB serum
levels while liver cirrhosis (LC) patients revealed lower sMICB serum levels (P < 0.0001) compared to other patient
groups. Notably, the sMICB serum levels were decreased in treated HCC patient group compared to not-treated
HCC patient group (P = 0.05). Additionally, the sMICB levels were significantly correlated with platelet counts in
ASYM and HCC patients (r = −0.37, P = 0.009; and r = 0.22, P = 0.025, respectively).
Conclusions: Our results demonstrate a potential role of sMICB serum levels and platelet counts during immune
response to the HBV infection, liver disease progression and response to the HCC treatment.
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Hepatitis caused by hepatitis B virus (HBV) is one of the
major global health problems with an estimate of at least
two billion people who had been infected with HBV.
More than 240 million chronic HBV carriers and approxi-
mately 600,000 deaths were recorded annually either due
to hepatitis B throughout the world [1]. HBV infection* Correspondence: toannl@vmmu.edu.vn
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unless otherwise stated.leads to a wide spectrum of pathologies including subclin-
ical, acute self-limited (AHB) and fulminant hepatitis, an
asymptomatic carrier state (ASYM), chronic hepatitis
(CHB) progressing to liver cirrhosis (LC) and life threaten-
ing hepatocellular carcinoma (HCC). Approximately 50%
of all HCC cases in childhood worldwide are caused by
HBV infection [2]. HBV is highly prevalent in sub-Saharan
Africa, Southeast Asia and parts of America with the in-
fection rates ranging from 8% to 20%. In Southeast Asia,
Vietnam has documented a prevalence of chronic hepa-
titis B up to 20% in the population, with approximately 10
million people living with chronic hepatitis B. In Vietnam,
23,300 deaths were registered in 2005, and nearly 27.1% ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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effect of national HBV vaccination program may pos-
sibly diminish the prevalence of HBV infection in the
next few years, the incidence and prevalence of HBV-
related diseases including LC and HCC were predicted
to be gradually increasing for the next two decades due
to the long latency of chronic hepatitis B [6].
Chronic HBV infection has been described as a high
risk factor of HCC development with a 100-fold increase
in chronic HBV carriers compared to non-carriers [5,7,8].
However, other factors including the geographical region,
ethnicity, prolonged use of alcohol, environmental factors
and hepatitis C virus (HCV) infection also significantly
contribute to the HCC incidence [7]. The mechanisms
and pathogenesis by which HBV induces HCC still need
a detailed investigation. However, several mechanisms
were proposed and partly demonstrated including the
immune response to infected liver cells during inflam-
mation due to HBV infection, the instability of host
chromosome due to the integration of HBV-DNA,
modulation and mutation in the coding genes or onco-
genes, and the interaction between viral HBx protein with
host signaling proteins consequently modulate the hepato-
cyte proliferation [9,10].
Several therapeutic interventions for HCC including
transcatheter oily chemoembolization (TOCE), radio-
frequency ablation (RFA), alcohol injection and surgi-
cal resection are in place. The choice of treatment
mostly depends on the stage of cancer which typically
determined based on the Child-Pugh classification sys-
tem [7]. Additionally, the possible new prognostic bio-
markers such as serum and tissue levels of vascular
endothelial growth factor (VEGF) and C-C motif che-
mokine ligand 15 (CCL15) have been recently identi-
fied [11,12]. However, the consideration of using these
biomarkers in clinical practice is still needed to be
investigated.
Many studies have demonstrated the clinical signifi-
cance of platelets in HBV-related liver diseases including
HCC [13-18]. Of which, different mechanisms leading to
thrombocytopenia including abnormal platelet produc-
tion, destruction and platelet-specific glycoproteins levels
have been proposed in HBV-related liver disease [13,15].
The blood platelets have been shown in vitro to induce
growth and invasion of several HCC cell lines [18]. In clin-
ical observations, high blood platelet counts were associ-
ated with extrahepatic metastasis [16] and with increased
tumor size [17]. In HCC treatment, anti-platelet therapy
showed a potential effect on inhibition of HBV-related
HCC development in a mouse model [19,20]. Therefore,
it would be important to investigate the correlations be-
tween platelet counts and clinical parameters during
progression of HBV-related liver diseases and response
to HCC treatment.Human major histocompatibility complex (MHC) class
I polypeptide-related sequence B (MICB) belongs to the
MIC family located within the MHC class I region of
chromosome 6 and consists of two functional genes
MICA and MICB and five pseudogenes MICC to MICG.
The MICB gene is 12,930 bp long and contains 6 exons
which encoding a protein of 383 amino acids [21]. Similar
to MICA, MICB protein interacts with the natural
killer cell receptor NKG2D and T cell receptor (TCR)
and consequently activates the natural killer (NK) cells,
gamma-delta (γδ) T cells and alpha-beta (αβ) CD8+ T
cells [22-24]. These activated effector cells (NK, γδT
and αβ CD8+ T cells) have been described to modulate
immune responses such as anti-tumor, viral infection
and autoimmune diseases [21-24]. In particular, NK
cells have been shown to play an important role during
HBV infection and progression of liver diseases includ-
ing LC and HCC [25,26]. In addition, MICB protein is
also expressed mainly in fibroblasts and epithelial as
well as in different cancer cell lines such as cervical
cancer and myelomonocytic leukemia [21,27,28]. Also,
soluble MICB serum levels were associated with vari-
ous diseases such as multiple sclerosis, liver diseases
and cancers [29-33]. However, to the best of our know-
ledge there was no study regarding the role of sMICB
during HBV infection and the possible association with
response to the treatment of HBV-related HCC. In this
study, we aim to analyze and validate the prognostic
potential of sMICB protein in the progression of HBV-




Two hundred and sixty six adult HBV-infected Vietnamese
patients were recruited in this study and enrolled at the
Tran Hung Dao and 103 Military hospitals of Hanoi,
Vietnam during 2012. The study was designed as a
cross-sectional study combined with clinical and experi-
mental observations. The patients were classified into
five subgroups based on the clinical, biochemical and
serological diagnosis and symptomatic patients with
histological examination following liver biopsy into
those with or without evidence of either cirrhosis or car-
cinoma. The patient subgroups include asymptomatic
HBV carriers (ASYM; n = 48), chronic hepatitis B (CHB;
n = 42), liver cirrhosis (LC; n = 49), hepatocellular car-
cinoma patients without liver cirrhosis (HCC; n = 102)
and hepatocellular carcinoma patients with liver cirrho-
sis (HCC + LC, n = 25). All study subjects were con-
firmed positive for HBsAg and negative for anti-HCV
and anti-HIV. Forty eight healthy Vietnamese blood
donors (HC) were included as a control group. The
healthy individuals were examined for their healthy
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and anti-HIV and none of them had a history of alcohol
or drug use. All clinical and serological parameters were
measured by routine laboratory tests.
Ethical statement
Informed written consent was received from all studied
participants. The study was approved by the Institutional
Review Board of the Vietnam Military Medical University
(VMMU).
Classification of hepatitis B patients
The clinical course and severity of hepatitis infections,
liver biochemical tests, serological markers of HBV in-
cluding diagnostic tests for HCC in the chronic HBV
infected patients were described as detailed elsewhere
[34,35]. Biopsies were taken from all patients with sus-
pected chronic HBV including LC and HCC. The pa-
tients were then classified on the basis of detailed
histological examination, into those with or without
evidence of either cirrhosis or carcinoma. In the latter
case, the degree of differentiation was noted. Individ-
uals with neither cirrhosis nor carcinoma were attrib-
uted a histological activity index according to the
scheme expression on hepatocytes observed by earlier
studies [35-37].Table 1 Characteristics of study subjects segregated accordin
Characteristics ASYM (n = 48) CHB (n = 42)
Age (years) 36 [18–57] 39 [20–69]
Gender (M/F) 35/13 33/9
WBC* 109/L 6.7 [4.8–11] 5.99 [4.8–11.8]
RBC* 1012/L 5 [3.8–47] 4.8 [3.8–11.6]
PLT* 109/L 227 [117–376] 217 [117–332]
ALT* (IU/L) 23 [8–74] 47 [13–750]
AST* (IU/L) 25 [12–35] 38 [19–599]
Total bilirubin* (mg/dl) 13 [6.7–32] 16 [8–32]
Direct bilirubin* (mg/dl) 3.5 [1–8] 5.7 [1.4–26]
Albumin* (g/L) 42 [38–48] 43 [12–48]
Prothrombin* (% of standard) 92 [78–127] 94 [72–127]
HBV viral load* (copies/ml) 6.65×104 5.53×105
[290–6.26×109] [100–9.9×108]




Alcohol injection NA NA
Surgery NA NA
ASYM, asymptomatic; CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellula
and ALT, aspartate and alanine amino transferase; IU, international units; TOCE, tran
applicable. Values given are medians and range; (*) P < 0.05 for comparison with allTherapeutic intervention of hepatocellular carcinoma
Of the 127 HCC patients, 76 were treated either with
transcatheter oily chemoembolization (TOCE), radiofre-
quency ablation (RFA), percutaneous ethanol injection
(PEI) or surgical resection. Of which, 12 patients were
treated with TOCE, RFA and alcohol injection, 23 patients
were treated with both TOCE and RFA, 25 patients were
treated with both TOCE and alcohol infection, and 15
patients were treated with both RFA and alcohol injec-
tion. Six patients who not received any non-surgical
therapeutic intervention were intervened by surgical re-
section (Table 1). In addition, no antiviral therapy was
applied for the HCC patients at the time of sampling.
The patients were selected for treatment based on
tumor size, number of tumor, site of tumor and stage of
the liver cancer. The PEI was used for the patients who
had liver tumors 3–5 cm and the RFA was used for the
patients with 1 tumor < 5 cm, or 3 tumors < 3 cm in size
whereas the TOCE was used for the patients who had
many tumors and/or big tumors and based on other fac-
tors such as the current condition of patients and liver
function. Not-treated HCC patients were at later stage
of liver cancer, with decompensated liver cirrhosis and/
or with metastasis. We collected samples from all of the
76 treated HCC patients one month after the course of
therapy has been finished and the patients were notg to clinical status
LC (n = 49) HCC (n = 102) HCC with LC (n = 25)
57 [27–79] 54.5 [26–81] 60 [40–75]
41/8 102/0 25/0
5.6 [3.2–18] 6 [2.7–17] 5.6 [3–8.4]
4.2 [2.5–5.7] 4.5 [2.43–6] 4 [3–5.2]
98 [3.7–320] 166 [40–382] 142 [35–226]
57 [13–395] 42 [12–805] 46 [11–290]
84 [15–329] 54.5 [17–670] 116 [25–655]
29 [9–571] 18 [8–184] 27 [9.6–185]
10 [0.4–291] 6 [1–80] 12.5 [2–59]
30 [3.3–47] 38 [4–47] 32 [22–42]
65 [23.4–92] 78 [19.6–128] 69 [36–124]
8.85×105 5.94×105 4.05×105
[203–4.71×108] [190–2.28×109] [2040–3.04×109]






r carcinoma; WBC, white blood cells; RBC, red blood cells; PLT, platelets; AST
scatheter oily chemoembolization; RFA, radiofrequency ablation; NA, not
other groups.
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tients, samples were collected at the time of admission
to the hospital. No evidence of side effects in treated
HCC patients was observed and there was no time win-
dow for these treated HCC patients.
Quantification of sMICB serum levels
Soluble MICB serum levels were measured in the sera
from the HBV infected patient groups and in healthy
controls using a commercially available MICB Human
ELISA Kit (Abcam, Tokyo, Japan; Catalog No. ab100593)
following the manufacturer’s instructions. Briefly, standard
and sample were added into appropriate wells of coated
ELISA plate and incubated over night at 4°C with gentle
shaking. Plates were washed with wash solution and sub-
sequently biotinylated MICB detection was added to each
well and was incubated at room temperature with gentle
shaking. After removing the solution and washing the
plates, HRP-Streptavidin solution was added to each well
and incubated at room temperature with gentle shaking.
The plates were washed again and TMB One-Step sub-
strate reagent was added to each well, incubated at room
temperature in the dark with gentle shaking. Finally, stop
solution was added to each well and plates were read at
450 nm immediately. The standard curve was plotted
log-log graph paper based upon the mean of absorbance
and the best fit straight line was drawn through the
standard points. The concentrations of sMICB serum
protein were calculated based upon the standard curve.
The minimum detectable limit of sMICB serum pro-
teins was 0.069 ng/ml.
Statistical analysis
Clinical and demographic data were presented using me-
dian with range for continuous variables and the student
t tests were used for comparisons of two groups.
Kruskal-Wallis or Mann–Whitney U test was used to
analyze the sMICB serum levels in patients and in
healthy controls and the association of sMICB serum
levels with the treatments of HCC where appropriate.
The Spearman’s rank correlation coefficient or Pearson
product–moment correlation coefficient was used to
analyze the correlation of sMICB serum level with clin-
ical and laboratory parameters where appropriate. All
statistical analysis was performed using IBM Statistics
SPSS v.19 and the level of significance was set at a P value
of less than 0.05.
Results
Clinical characteristics of the studied patients
The main clinical and demographic characteristics such
as age, gender, liver biochemical tests, viral load and the
tumor marker alpha-feto protein for all the investigated
266 Vietnamese hepatitis B patients and 48 healthycontrols are summarized in Table 1. The white blood
cells, red blood cells and platelet counts were decreased
in CHB, LC and HCC groups compared to the ASYM
group. The platelet counts were observed significantly
lower in LC and HCC groups compared to ASYM and
CHB (P < 0.0001). Levels of laboratory parameters such
as ALT, AST, total and direct bilirubin and HBV-DNA
loads were significantly higher in CHB, LC and HCC
groups compared to ASYM group whereas the levels of
albumin and prothrombin were significantly decreased
in LC and HCC groups compared to ASYM and CHB
(P < 0.001). As expected, the level of the tumour marker
alpha-feto protein was observed significantly higher in
HCC patients compared to LC patients (P < 0.001).
Furthermore, the levels of AST and alpha-feto protein
were significantly elevated in HCC patients with liver
cirrhosis compared to HCC patients without liver cir-
rhosis (P < 0.001) (Table 1).
Soluble MICB serum levels in hepatitis B patients
Soluble MICB (sMICB) serum levels were determined in
266 studied HBV patients and 48 healthy controls. We
observed a median of 29.07 ng/ml [8.5-37.9] in ASYM,
26.5 ng/ml [0.1-41.3] in CHB, 21.5 ng/ml [2.6-36.8] in
LC, 18.35 ng/ml [3.14-195.7] in HCC patients without
cirrhosis and 23.6 ng/ml [3.14-118] in HCC patients
with cirrhosis. Analyzing healthy controls only a median
of 5.6 ng/ml [0.1-25.04] could be detected. The results
demonstrated that the sMICB serum levels were signifi-
cantly elevated in HBV patients compared to healthy
controls (P < 0.0001) (Figure 1). The sMICB serum levels
varied in the patient subgroups, of which, sMICB serum
levels were significantly higher in ASYM compared to
LC and HCC patient groups (P < 0.0001, and P = 0.029,
respectively). Significantly lower sMICB serum levels
were observed in the LC patient group in comparison to
the CHB patient group (P = 0.038). There was no signifi-
cant difference of the sMICB serum levels in comparison
between ASYM and CHB, CHB and HCC as well as be-
tween LC and HCC patient groups (P > 0.05). Although
compared with HCC patients without liver cirrhosis, pa-
tients with liver cirrhosis have a small increase of sMICB
level, there was no significance (P > 0.05) (Figure 1).
Relationship between sMICB serum levels and clinical
parameters
In order to analyze the relationship between sMICB
serum levels and clinical parameters, the sMICB serum
levels were correlated with all available clinical and labora-
tory parameters in the different HBV-infected patient
groups. In pooled HBV patients, we notably observed a
significantly positive correlation between sMICB serum
levels and platelet counts (Spearman’s rho = 0.22, P < 0.0001)
(Figure 2A). However, the sMICB serum levels were not
Figure 1 sMICB serum levels in patient groups and healthy controls. Soluble MICB serum levels were measured in different subgroups of
patient and healthy controls. HC: healthy control, ASYM: asymptomatic, CHB: chronic hepatitis B, LC: liver cirrhosis, HCC: hepatocellular carcinoma.
Numbers in parentheses are number of samples measured, (*): P < 0.0001 in comparisons of healthy controls with different patient groups using
two sided Mann–Whitney U test.
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AST, total and direct bilirubin, albumin, prothrombin,
AFP and HBV-DNA viral loads. When patients were di-
vided into clinical subgroups, we observed that the
sMICB serum levels were significantly reverse corre-
lated with white blood cell counts and platelet counts in
ASYM group (Pearson’s r = −0.323, P = 0.024 and Pearson’s
r = −0.37, P = 0.009, respectively) (Figure 3A and B). We
also observed a positive correlation between sMICB
serum levels and platelet counts in LC and HCC groups
(Pearson’s r = 0.27, P= 0.06 and Pearson’s r = 0.22, P= 0.025,
respectively) (Figure 3C and D). However, no significant
correlations were observed between sMICB serum levels
and several available clinical and laboratory parameters in
CHB patient group (data not shown).
Soluble MICB serum levels and hepatocellular carcinoma
treatment
Of the 127 studied HCC patients, 76 HCC patients were
treated with different cancer therapies including trans-
catheter oily chemoembolization (TOCE), radiofrequency
ablation (RFA), alcohol injection and surgical resection.The remaining 51 HCC patients were yet to be treated
with any cancer therapies. Analysis of the sMICB serum
levels in treated versus not-treated HCC patient groups,
we observed a decreased sMICB serum level in treated
HCC patient group compared to not-treated HCC patient
group (P = 0.05) (Figure 4A). However, there were no sig-
nificant differences of sMICB serum levels in different
modalities of therapeutic interventions (data not shown).
In contrast, the red blood cell counts were significantly
decreased in treated HCC patient group compared to not-
treated HCC patient group (P = 0.009). The platelet counts
decreased but with no statistically significance in treated
HCC patients compared with not-treated HCC patients
(P = 0.105) (Figure 4B and C).
Discussion
Human major histocompatibility complex (MHC) class I
polypeptide-related sequence B (MICB), together with
MICA are ligands of the NKG2D receptor. The inter-
action between NKG2D receptor and its ligand results
in an activation of NK cells, γδ T cells and αβ CD8+ T
cells which play a crucial role during viral infection,
Figure 2 Correlation between sMICB serum levels and platelet counts in HBV patients. The sMICB serum levels were correlated with
platelet count using Spearman’s rank correlation coefficient test. The Spearman’s rho and P value are also presented.
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this study, we investigated the levels of sMICB serum
protein in different stages of HBV infection and its role
in HCC treatment. Our results showed that the sMICB
serum levels were significantly increased in HBV pa-
tients compared to healthy controls (P < 0.0001), signifi-
cantly decreased in treated HCC patients compared to
not-treated HCC patients (P = 0.05), and significantly
correlated with platelet count in ASYM, LC and HCC
patients. These findings propose that sMICB serum pro-
tein significantly contribute to in immune response to
the HBV infection, plays a role in progression of liver
diseases and is possibly considered as biomarker for re-
sponse to HCC treatment.
The increased sMICB serum protein has been previ-
ously demonstrated to correlate with different cancers
compared to healthy individuals [29-33]. Several studies
revealed that elevated sMICB serum levels were corre-
lated with stages of tumor and metastasis as well as in
the progression of both HBV and HCC related liver dis-
eases [29,30]. In contrast, the sMICB serum levels in this
study were not elevated with the progression of liver dis-
eases. The contrary results could be explained by the
cellular stress response mechanisms during HBV infec-
tion by which the promoter heat shock elements regu-
late the expression of MICA and MICB similar to those
of HSP70 [38]. This hypothesis is supported by severalstudies which demonstrate that MICB was not only
expressed in tumor cells but also in different non-tumor
cell lines under stress conditions [27,28,39,40]. There-
fore, due to viral infections and long-term inflammation,
MIC proteins (MICA and MICB) can be over-expressed.
In addition, the higher sMICB serum levels were ob-
served in asymptomatic HBV carriers that are consistent
with several previous studies which reported the elevated
sMICA serum levels in early stage of viral infection
[41,42] and inferred that MICA expression was induced
by viral infection through cellular stress response mech-
anisms [42]. A very recent study has shown that over-
expression of HBsAg suppresses the expression of MICA
and MICB via induction of several cellular miRNAs [43].
Therefore, lower levels of sMICB protein in the patients
with chronic hepatitis B, LC and HCC could be best ex-
plained by the high levels of HBsAg due to the higher
level of HBV replication in the later stage of HBV infec-
tion such as LC and HCC. A limitation of our study is
that the information for antiviral therapy of the CHB
and LC patients was not completed therefore we could
not analyze the effect of antiviral therapy on sMICB
level. Nevertheless, we assume that the antiviral therap-
ies possibly influence the sMICB level and further stud-
ies are needed to verify the hypothesis.
Concerning the role of sMICB in HCC treatment, our
results showed that sMICB serum levels were decreased
Figure 3 Correlation between sMICB serum levels and clinical parameters in HBV patient groups. The sMICB serum levels were correlated
with platelet count and white blood cell count using Pearson product–moment correlation coefficient test. The Pearson’s r and P values are also
presented. (A): correlation between sMICB serum levels and white blood cell count in asymptomatic HBV carriers, (B): correlation between sMICB
serum levels and platelet in asymptomatic HBV carriers, (C): correlation between sMICB serum levels and platelet in liver cirrhosis patients,
(D): correlation between sMICB serum levels and platelet in hepatocellular carcinoma patients.
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patients but were not associated with different modal-
ities of HCC treatment. Conversely, earlier study showed
that the sMICB serum levels were strongly increased in
melanoma patients treated with cytostatics compared to
untreated patients. However, other therapy such as IFN-α
treatment did not affect the sMICB serum levels [33]. In
addition, another study showed that there was no signifi-
cant difference of sMICB serum levels between multiple
sclerosis patients with or without immunomodulatory
treatment [44]. Hence, different therapy modalities might
inversely affect the sMIC (sMICA and sMICB) serum
levels. In case of HCC, a study has indicated that the
sMICA serum levels, but not sMICB serum levels,
were significantly decreased after transcatheter arterial
embolization (TAE) therapy. However, when analyzing
the subpopulation of the HCC patient group in our
study, sMICB serum levels were decreased in HCC pa-
tients with compensated cirrhosis in contrast to HCC pa-
tients with mildly decompensated cirrhosis and severely
decompensated cirrhosis [30]. Due to the important rolesof MIC proteins in modulation of immune response, a
study has proposed that serum tests of sMICA and sMICB
in combination with tumor measurements could be con-
sidered to enhance the effectiveness of immune thera-
peutic interventions [45]. From our results, we suggest
that sMICB and sMICA serum levels [30,42,46] could
serve as a biomarker for monitoring treatment outcome
of HBV-induced HCC.
A recent study using a mouse model of chronic
immune-mediated hepatitis B has indicated that anti-
platelet drugs effectively prevent HCC and improve sur-
vival suggesting that platelets could play a crucial role in
the pathogenesis of HBV-associated liver cancer [19,20].
In agreement with this study, our results indicated that
the platelet counts were significantly decreased accord-
ing to the progression of liver disease. Interestingly, we
observed a positive correlation between sMICB serum
levels and platelet counts in studied HBV infected pa-
tients and in patient subgroups including LC and HCC
whereas an inverse correlation was observed in ASYM
carriers. An explanation for that finding could be a
Figure 4 sMICB serum levels and clinical parameters according to HCC treatment. (A): The sMICB serum levels in not-treated and treated
HCC patients. (B): Red blood cell counts in not-treated and treated HCC patients. (C): Platelet count in not-treated and treated HCC patients.
P values were calculated by using two sided Mann–Whitney U test.
Tong et al. BMC Infectious Diseases  (2015) 15:25 Page 8 of 10strong decrease of platelet counts in the later stage of
liver disease like LC and HCC while the sMICB serum
levels were not decreased or even increased during HCC
pathogenesis. However, the platelet counts were not dif-
ferent between HCC patients with and without treat-
ment indicating that the therapeutic interventions
employed in our study did not affect the platelet counts.
The platelets have been proposed to be recruited into
the liver and facilitate the hepatic accumulation of virus
specific CD8+ T cells which immune-mediated liver in-
jury during HBV infection [20,47]. Additionally, platelets
were also implied to be involved in accumulation of
virus-nonspecific CD8+ T cells and other virus-nonspecific
inflammatory cells including NK cells during acute hepatitis
in a mouse model [19,20,47]. Recent reports have shown
that the platelet counts were inverse correlated with mean
platelet volume and suggested that mean platelet volume
could determine the severity of liver fibrosis and inflamma-
tion in CHB patients [48,49]. The observation of lowest
platelet counts in the LC group in our study compared to
other HBV patient groups may support earlier findingsthat platelets could be a crucial player during progression
of LC and HCC [19,20]. In addition, post-operative low
platelet counts have been shown to be associated with
poor outcome after hepatic resection for HCC suggesting
an important role of platelets during liver compensation
[50]. However, further detailed studies are needed to detail
the clinical role of platelets during liver disease and im-
mune response in HCC treatment.Conclusion
Our results showed elevated sMICB serum levels in differ-
ent stages of liver disease progression compared to healthy
controls, and decreased sMICB serum levels in treated
HCC patients compared to untreated HCC patients. Not-
ably, sMICB serum levels were significantly correlated
with platelet counts which were speculated recently as a
key player during development of liver cirrhosis and hepa-
tocellular carcinoma therapy. Our findings suggest that
sMICB could play a vital role during HBV infection, liver
disease progression and HCC treatment.
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